Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRM-1 in Relapsed or Refractory NSCLC
NCT00092924Phase 2Completed
- Sponsor
- Human Genome Sciences
- Primary completion
- Jan 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mapatumumab in non-small cell lung cancer (NSCLC), sponsored by Human Genome Sciences. Primary endpoints: Objective Response Rate and Safety and Tolerability. Status: completed.
02
Drugs
mapatumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00092924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092924.